Top Gene Panel Companies

Gene Panel Market size was valued at USD 3.41 Billion in 2024 and is poised to grow from USD 4.07 Billion in 2025 to USD 16.7 Billion by 2033, growing at a CAGR of 19.3% during the forecast period (2026–2033).

Global gene panel market is competitive with key players who drive innovations and expand markets. To keep up with the high demand for personalized medicine, rapid technological advancements have continued fueling competition among these companies that specialize in gene panels like Illumina, Thermo Fisher Scientific or Agilent Technologies and offer advanced sequencing technologies in addition to complete solutions for gene panels. Fast technology progressions and a growing desire for individualized treatment are spurring on going innovations as well as frequent expansion in the market. 'Qiagen  ', 'Roche  ', 'Illumina  ', 'Thermo Fisher Scientific  ', 'Agilent Technologies  ', 'Bio-Rad Laboratories  ', 'PerkinElmer  ', 'Becton, Dickinson and Company (BD)  ', 'Sangamo Therapeutics  ', 'Genomics England ', 'Personalis, Inc.  ', 'Twist Bioscience Corporation ', 'Castle Biosciences, Inc ', 'Neogenomics Laboratories  ', 'NantHealth  ', 'Macrogen  ', 'Myrtelle Inc.  ', 'Eurofins Genomics ', 'Guardant Health, Inc. ', 'Myriad Genetic Laboratories Inc.'

The global gene panel market is being driven by innovations of next-generation sequencing (NGS) technologies that offer better precision, increased pace and cost savings for genetic analysis. This has made it possible to have extensive genomic profiling and thus encourage personalization of medicine hence stimulating the demand for gene panels in clinical and research applications.

Surge in Personalized Medicine Adoption: Personalized medicine is on the rise in the global gene panel market as healthcare practitioners are using gene panels more frequently for customized treatment approaches. Such a trend that has been fueled by advancements in genomics has enabled better diagnostics and focused therapies that can improve patients’ health outcomes thus boosting demand for these products.

North America dominates the global gene panel market due to its advanced healthcare infrastructure, high investment in biotechnology research, and a strong focus on personalized medicine. Through the allocation of massive funds for genomic research within this region, one can observe that there are strong regulatory structures already in place as well as a high uptake of advanced technologies. Demand for complex gene panels in the US and Canadian regions is primarily driven by major pharmaceutical and biotechnology firms which have a solid network of hospitals and diagnostic laboratories. Other than that, the gene panel industry continues to grow due to North America's conducive policy environment and collaboration among researchers thereby fostering innovation.